{"id":3170,"date":"2022-01-17T01:24:33","date_gmt":"2022-01-17T00:24:33","guid":{"rendered":"https:\/\/www.oncology-and-cytogenetic-products.com\/omicron-2-the-stealth-variant-is-becoming-prevalent-in-denmark-and-in-many-asian-countries\/"},"modified":"2022-02-07T15:53:21","modified_gmt":"2022-02-07T14:53:21","slug":"omicron-2-the-stealth-variant-is-becoming-prevalent-in-denmark-and-in-many-asian-countries","status":"publish","type":"post","link":"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/omicron-2-the-stealth-variant-is-becoming-prevalent-in-denmark-and-in-many-asian-countries\/","title":{"rendered":"Omicron-2, the \u201cstealth\u201d variant is becoming prevalent in Denmark and in many Asian countries"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.9.3&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;0px||||false|false&#8221; custom_padding=&#8221;0px|||||&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.9.3&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;0px||||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.9.3&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.9.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p style=\"text-align: justify;\"><strong><\/strong><\/p>\n<p><span style=\"font-weight: 400;\"><strong>Omicron<\/strong> or B.1.1.529, the last \u201cversion\u201d of SARS-CoV-2 original strain, <strong>was identified almost two months ago<\/strong>. <\/span><\/p>\n<p><span style=\"font-weight: 400;\">Today, Omicron <strong>is going to replace Delta variant prevalence in almost all countries<\/strong>.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">According to <\/span><a href=\"https:\/\/gis.ecdc.europa.eu\/portal\/apps\/opsdashboard\/index.html#\/25b6e879c076412aaa9ae7adb78d3241\"><span style=\"font-weight: 400;\">ECDC monitor of Gisaid data<\/span><\/a><span style=\"font-weight: 400;\">, at the moment we write, Omicron variant <strong>is already prevalent in all European countries<\/strong>, with a distribution percentage close to 60% while Delta, the once-dominant, nowadays is close to 30%.\u00a0<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-size: 14px;\"><span style=\"font-weight: 400;\">Different data are coming, instead, <\/span><a href=\"https:\/\/covid.cdc.gov\/covid-data-tracker\/#variant-proportions\"><span style=\"font-weight: 400;\">from the US<\/span><\/a><span style=\"font-weight: 400;\">: while the variant trend is similar to European countries, Omicron proportion is now near to <strong>100% in almost all States<\/strong>.<\/span><\/span><\/p>\n<h2 style=\"text-align: left;\">Omicron BA.2 variant highly underestimate<\/h2>\n<p style=\"text-align: justify;\"><span style=\"font-weight: 400;\">Based on its genomic data, Omicron variant has been straight separated into <strong>three subgroups: BA.1, BA.2, and BA.3<\/strong>. <\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-weight: 400;\">These clades <strong>share most of their specific mutations except for the deletion used as the target for S Gene Target Failure<\/strong> (SGTF\/ S gene dropout) that is not present in BA.2. <\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-weight: 400;\">The <strong>too-quick decision<\/strong> made to adopt the\u00a0 SGTF molecular method to diagnose Omicron has therefore <strong>caused the underestimation of the variant cases<\/strong>. <\/span><\/p>\n<h2 style=\"text-align: left;\">What&#8217;s new?<\/h2>\n<p><strong>BA.2 cases are <a href=\"https:\/\/www.timesnownews.com\/health\/article\/new-highly-transmissible-omicron-sub-variant-ba-2-now-also-in-uk-53-cases-found\/849549\">spiraling<\/a><\/strong><span style=\"font-weight: 400;\">, gradually reaching the numbers of BA.1. <\/span><\/p>\n<p><span style=\"font-weight: 400;\">But this is not happening because the variant has reached a greater thrust, but probably <strong>because of the underestimation given by the SGTF inadequacy<\/strong>. <\/span><\/p>\n<p><b>SGTF is not valid for defining Omicron circulation: <\/b><span style=\"font-weight: 400;\">sequencing data have clearly defined this point.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">As <\/span><a href=\"https:\/\/www.oncology-and-cytogenetic-products.com\/ineffectiveness-of-the-sgtf-with-omicron-clade-ba-2\/\"><span style=\"font-weight: 400;\">we have been saying<\/span><\/a><span style=\"font-weight: 400;\"> since Omicron first appearance, <\/span><b>the only way to make a diagnosis is through a positive detection and not through a negative analysis<\/b><span style=\"font-weight: 400;\">. <\/span><\/p>\n<p><span style=\"font-weight: 400;\">Omicron variants (BA.1, BA.2, and BA.3) <strong>must be diagnosed by detecting their own characteristic single-base mutations<\/strong> and not by the absence of a region and therefore the absence of a signal.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Most of the media <\/span><a href=\"https:\/\/timesofindia.indiatimes.com\/city\/hyderabad\/rt-pcr-unlikely-to-identify-omicron-variant-ba-2-experts\/articleshow\/88175592.cms\"><span style=\"font-weight: 400;\">reporting<\/span><\/a><span style=\"font-weight: 400;\"> new BA.2 spreading claim that PCR test failed to detect the variant, <\/span><b>but things are different: SGTF test has failed<\/b><span style=\"font-weight: 400;\">.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Since it\u2019s impossible to sequence all the samples due to a matter of time and costs required, <\/span><b>it\u2019s necessary that all the laboratories work to provide diagnosis using PCR tests able to detect specific SARS CoV-2 genes mutations<\/b><span style=\"font-weight: 400;\"> besides not mutated genes (like our <a href=\"https:\/\/www.oncology-and-cytogenetic-products.com\/products\/covid-19-nucleic-acid-detection-kit-variants\/\">Covid VoC Rapid PCR Typing kit<\/a><\/span><span style=\"font-weight: 400;\">). This is the only way not to lose cases, variants, and mutations.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Although there is no evidence that the behavior of the BA.2 clade is different from the others, <strong>it is necessary to monitor its progression in a continuous and capillary way in order to not be surprised by the events<\/strong>.<\/span><\/p>\n<p style=\"text-align: right;\"><strong><em>Written by Simone Di Giacomo, PhD, OaCP R&amp;D Manager<\/em><\/strong><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.9.3&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;20px||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.9.3&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_divider divider_weight=&#8221;2px&#8221; _builder_version=&#8221;4.9.3&#8243; _module_preset=&#8221;default&#8221; width=&#8221;20%&#8221; module_alignment=&#8221;center&#8221; custom_margin=&#8221;||0px||false|false&#8221; custom_padding=&#8221;||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_divider][et_pb_text _builder_version=&#8221;4.14.6&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<blockquote class=\"twitter-tweet\">\n<p lang=\"en\" dir=\"ltr\">Here we go!<\/p>\n<p>A dominant BA.2 in Denmark on the 9th of January 2022.<\/p>\n<p>2 days later than I predicted and maybe some extra when data will be complete. But the 2k samples available on the 7th, make it quite clear were it was going already, if you ask me.<a href=\"https:\/\/t.co\/peK0Qpxl9Z\">https:\/\/t.co\/peK0Qpxl9Z<\/a> <a href=\"https:\/\/t.co\/wlSXOfBsDN\">pic.twitter.com\/wlSXOfBsDN<\/a><\/p>\n<p>&mdash; Josette Schoenmakers (@JosetteSchoenma) <a href=\"https:\/\/twitter.com\/JosetteSchoenma\/status\/1482110329035313153?ref_src=twsrc%5Etfw\">January 14, 2022<\/a><\/p><\/blockquote>\n<p> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Omicron or B.1.1.529, the last \u201cversion\u201d of SARS-CoV-2 original strain, was identified almost two months ago. Today, Omicron is going to replace Delta variant prevalence in almost all countries.\u00a0 According to ECDC monitor of Gisaid data, at the moment we write, Omicron variant is already prevalent in all European countries, with a distribution percentage close [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":3127,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[54],"tags":[],"class_list":["post-3170","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-covid-19-insights-it"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.1.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Omicron-2, the \u201cstealth\u201d variant is becoming prevalent in Denmark and in many Asian countries - OaCP<\/title>\n<meta name=\"description\" content=\"Most of the media reporting new BA.2 spreading claim that PCR test failed to detect the variant, but things are different: SGTF test failed.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.oncology-and-cytogenetic-products.com\/omicron-2-the-stealth-variant-is-becoming-prevalent-in-denmark-and-in-many-asian-countries\/\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Omicron-2, the \u201cstealth\u201d variant is becoming prevalent in Denmark and in many Asian countries - OaCP\" \/>\n<meta property=\"og:description\" content=\"Most of the media reporting new BA.2 spreading claim that PCR test failed to detect the variant, but things are different: SGTF test failed.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.oncology-and-cytogenetic-products.com\/omicron-2-the-stealth-variant-is-becoming-prevalent-in-denmark-and-in-many-asian-countries\/\" \/>\n<meta property=\"og:site_name\" content=\"OaCP\" \/>\n<meta property=\"article:published_time\" content=\"2022-01-17T00:24:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-02-07T14:53:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2022\/01\/OaCP-Josette-Schoenmakers-Delta-BA1-BA2-resized.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Andrea Faviere\" \/>\n<meta name=\"twitter:label1\" content=\"Scritto da\" \/>\n\t<meta name=\"twitter:data1\" content=\"Andrea Faviere\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo di lettura stimato\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minuti\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/omicron-2-the-stealth-variant-is-becoming-prevalent-in-denmark-and-in-many-asian-countries\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/omicron-2-the-stealth-variant-is-becoming-prevalent-in-denmark-and-in-many-asian-countries\/\"},\"author\":{\"name\":\"Andrea Faviere\",\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/#\/schema\/person\/f3323e37ce648e6f8ebd51aba3e8cd08\"},\"headline\":\"Omicron-2, the \u201cstealth\u201d variant is becoming prevalent in Denmark and in many Asian countries\",\"datePublished\":\"2022-01-17T00:24:33+00:00\",\"dateModified\":\"2022-02-07T14:53:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/omicron-2-the-stealth-variant-is-becoming-prevalent-in-denmark-and-in-many-asian-countries\/\"},\"wordCount\":650,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/omicron-2-the-stealth-variant-is-becoming-prevalent-in-denmark-and-in-many-asian-countries\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2022\/01\/OaCP-Josette-Schoenmakers-Delta-BA1-BA2-resized.jpg\",\"articleSection\":[\"COVID-19 Insights\"],\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.oncology-and-cytogenetic-products.com\/omicron-2-the-stealth-variant-is-becoming-prevalent-in-denmark-and-in-many-asian-countries\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/omicron-2-the-stealth-variant-is-becoming-prevalent-in-denmark-and-in-many-asian-countries\/\",\"url\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/omicron-2-the-stealth-variant-is-becoming-prevalent-in-denmark-and-in-many-asian-countries\/\",\"name\":\"Omicron-2, the \u201cstealth\u201d variant is becoming prevalent in Denmark and in many Asian countries - OaCP\",\"isPartOf\":{\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/omicron-2-the-stealth-variant-is-becoming-prevalent-in-denmark-and-in-many-asian-countries\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/omicron-2-the-stealth-variant-is-becoming-prevalent-in-denmark-and-in-many-asian-countries\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2022\/01\/OaCP-Josette-Schoenmakers-Delta-BA1-BA2-resized.jpg\",\"datePublished\":\"2022-01-17T00:24:33+00:00\",\"dateModified\":\"2022-02-07T14:53:21+00:00\",\"description\":\"Most of the media reporting new BA.2 spreading claim that PCR test failed to detect the variant, but things are different: SGTF test failed.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/omicron-2-the-stealth-variant-is-becoming-prevalent-in-denmark-and-in-many-asian-countries\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.oncology-and-cytogenetic-products.com\/omicron-2-the-stealth-variant-is-becoming-prevalent-in-denmark-and-in-many-asian-countries\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/omicron-2-the-stealth-variant-is-becoming-prevalent-in-denmark-and-in-many-asian-countries\/#primaryimage\",\"url\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2022\/01\/OaCP-Josette-Schoenmakers-Delta-BA1-BA2-resized.jpg\",\"contentUrl\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2022\/01\/OaCP-Josette-Schoenmakers-Delta-BA1-BA2-resized.jpg\",\"width\":1280,\"height\":720},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/omicron-2-the-stealth-variant-is-becoming-prevalent-in-denmark-and-in-many-asian-countries\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Omicron-2, the \u201cstealth\u201d variant is becoming prevalent in Denmark and in many Asian countries\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/#website\",\"url\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/\",\"name\":\"OaCP\",\"description\":\"Oncology and Cytogenetic Products\",\"publisher\":{\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/#organization\",\"name\":\"OACP IE LTD\",\"url\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2018\/10\/logo-OaCP.png\",\"contentUrl\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2018\/10\/logo-OaCP.png\",\"width\":159,\"height\":70,\"caption\":\"OACP IE LTD\"},\"image\":{\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/#\/schema\/person\/f3323e37ce648e6f8ebd51aba3e8cd08\",\"name\":\"Andrea Faviere\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/www.oncology-and-cytogenetic-products.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/762e80340f20c117281bda8dc6c0fb77c59236bdfad2a5aea61701d78bf09501?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/762e80340f20c117281bda8dc6c0fb77c59236bdfad2a5aea61701d78bf09501?s=96&d=mm&r=g\",\"caption\":\"Andrea Faviere\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Omicron-2, the \u201cstealth\u201d variant is becoming prevalent in Denmark and in many Asian countries - OaCP","description":"Most of the media reporting new BA.2 spreading claim that PCR test failed to detect the variant, but things are different: SGTF test failed.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.oncology-and-cytogenetic-products.com\/omicron-2-the-stealth-variant-is-becoming-prevalent-in-denmark-and-in-many-asian-countries\/","og_locale":"it_IT","og_type":"article","og_title":"Omicron-2, the \u201cstealth\u201d variant is becoming prevalent in Denmark and in many Asian countries - OaCP","og_description":"Most of the media reporting new BA.2 spreading claim that PCR test failed to detect the variant, but things are different: SGTF test failed.","og_url":"https:\/\/www.oncology-and-cytogenetic-products.com\/omicron-2-the-stealth-variant-is-becoming-prevalent-in-denmark-and-in-many-asian-countries\/","og_site_name":"OaCP","article_published_time":"2022-01-17T00:24:33+00:00","article_modified_time":"2022-02-07T14:53:21+00:00","og_image":[{"width":1280,"height":720,"url":"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2022\/01\/OaCP-Josette-Schoenmakers-Delta-BA1-BA2-resized.jpg","type":"image\/jpeg"}],"author":"Andrea Faviere","twitter_misc":{"Scritto da":"Andrea Faviere","Tempo di lettura stimato":"3 minuti"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/omicron-2-the-stealth-variant-is-becoming-prevalent-in-denmark-and-in-many-asian-countries\/#article","isPartOf":{"@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/omicron-2-the-stealth-variant-is-becoming-prevalent-in-denmark-and-in-many-asian-countries\/"},"author":{"name":"Andrea Faviere","@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/#\/schema\/person\/f3323e37ce648e6f8ebd51aba3e8cd08"},"headline":"Omicron-2, the \u201cstealth\u201d variant is becoming prevalent in Denmark and in many Asian countries","datePublished":"2022-01-17T00:24:33+00:00","dateModified":"2022-02-07T14:53:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/omicron-2-the-stealth-variant-is-becoming-prevalent-in-denmark-and-in-many-asian-countries\/"},"wordCount":650,"commentCount":0,"publisher":{"@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/#organization"},"image":{"@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/omicron-2-the-stealth-variant-is-becoming-prevalent-in-denmark-and-in-many-asian-countries\/#primaryimage"},"thumbnailUrl":"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2022\/01\/OaCP-Josette-Schoenmakers-Delta-BA1-BA2-resized.jpg","articleSection":["COVID-19 Insights"],"inLanguage":"it-IT","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.oncology-and-cytogenetic-products.com\/omicron-2-the-stealth-variant-is-becoming-prevalent-in-denmark-and-in-many-asian-countries\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/omicron-2-the-stealth-variant-is-becoming-prevalent-in-denmark-and-in-many-asian-countries\/","url":"https:\/\/www.oncology-and-cytogenetic-products.com\/omicron-2-the-stealth-variant-is-becoming-prevalent-in-denmark-and-in-many-asian-countries\/","name":"Omicron-2, the \u201cstealth\u201d variant is becoming prevalent in Denmark and in many Asian countries - OaCP","isPartOf":{"@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/omicron-2-the-stealth-variant-is-becoming-prevalent-in-denmark-and-in-many-asian-countries\/#primaryimage"},"image":{"@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/omicron-2-the-stealth-variant-is-becoming-prevalent-in-denmark-and-in-many-asian-countries\/#primaryimage"},"thumbnailUrl":"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2022\/01\/OaCP-Josette-Schoenmakers-Delta-BA1-BA2-resized.jpg","datePublished":"2022-01-17T00:24:33+00:00","dateModified":"2022-02-07T14:53:21+00:00","description":"Most of the media reporting new BA.2 spreading claim that PCR test failed to detect the variant, but things are different: SGTF test failed.","breadcrumb":{"@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/omicron-2-the-stealth-variant-is-becoming-prevalent-in-denmark-and-in-many-asian-countries\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.oncology-and-cytogenetic-products.com\/omicron-2-the-stealth-variant-is-becoming-prevalent-in-denmark-and-in-many-asian-countries\/"]}]},{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/omicron-2-the-stealth-variant-is-becoming-prevalent-in-denmark-and-in-many-asian-countries\/#primaryimage","url":"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2022\/01\/OaCP-Josette-Schoenmakers-Delta-BA1-BA2-resized.jpg","contentUrl":"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2022\/01\/OaCP-Josette-Schoenmakers-Delta-BA1-BA2-resized.jpg","width":1280,"height":720},{"@type":"BreadcrumbList","@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/omicron-2-the-stealth-variant-is-becoming-prevalent-in-denmark-and-in-many-asian-countries\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/"},{"@type":"ListItem","position":2,"name":"Omicron-2, the \u201cstealth\u201d variant is becoming prevalent in Denmark and in many Asian countries"}]},{"@type":"WebSite","@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/#website","url":"https:\/\/www.oncology-and-cytogenetic-products.com\/","name":"OaCP","description":"Oncology and Cytogenetic Products","publisher":{"@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.oncology-and-cytogenetic-products.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"},{"@type":"Organization","@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/#organization","name":"OACP IE LTD","url":"https:\/\/www.oncology-and-cytogenetic-products.com\/","logo":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2018\/10\/logo-OaCP.png","contentUrl":"https:\/\/www.oncology-and-cytogenetic-products.com\/wp-content\/uploads\/2018\/10\/logo-OaCP.png","width":159,"height":70,"caption":"OACP IE LTD"},"image":{"@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/#\/schema\/person\/f3323e37ce648e6f8ebd51aba3e8cd08","name":"Andrea Faviere","image":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.oncology-and-cytogenetic-products.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/762e80340f20c117281bda8dc6c0fb77c59236bdfad2a5aea61701d78bf09501?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/762e80340f20c117281bda8dc6c0fb77c59236bdfad2a5aea61701d78bf09501?s=96&d=mm&r=g","caption":"Andrea Faviere"}}]}},"_links":{"self":[{"href":"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/wp-json\/wp\/v2\/posts\/3170","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/wp-json\/wp\/v2\/comments?post=3170"}],"version-history":[{"count":1,"href":"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/wp-json\/wp\/v2\/posts\/3170\/revisions"}],"predecessor-version":[{"id":3171,"href":"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/wp-json\/wp\/v2\/posts\/3170\/revisions\/3171"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/wp-json\/wp\/v2\/media\/3127"}],"wp:attachment":[{"href":"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/wp-json\/wp\/v2\/media?parent=3170"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/wp-json\/wp\/v2\/categories?post=3170"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.oncology-and-cytogenetic-products.com\/it\/wp-json\/wp\/v2\/tags?post=3170"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}